Literature DB >> 19574339

Corynebacterium peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases.

Katherine Barraclough1, Carmel M Hawley, Stephen P McDonald, Fiona G Brown, Johan B Rosman, Kathryn J Wiggins, Kym M Bannister, David W Johnson.   

Abstract

BACKGROUND: Infection due to Corynebacterium species has been reported with increasing frequency over recent decades. The impacts of enhanced laboratory detection together with widespread use of new peritoneal dialysis (PD) connection technology and antimicrobial prophylaxis strategies on Corynebacterium PD-associated peritonitis have not been well studied.
METHODS: We investigated the frequency, predictors, treatment and clinical outcomes of Corynebacterium peritonitis in all Australian adult patients involving 66 centres who were receiving PD between 1 October 2003 and 31 December 2006.
RESULTS: Eighty-two episodes of Corynebacterium peritonitis (2.3% of all peritonitis episodes) occurred in 65 (1.4%) PD patients. Ten (15%) patients experienced more than one episode of Corynebacterium peritonitis and additional organisms were isolated in 12 (15%) episodes of Corynebacterium peritonitis. The incidence of Corynebacterium peritonitis was significantly and independently predicted only by BMI: RR 2.72 (95% CI 1.38-5.36) for the highest tertile BMI compared with the lowest tertile. The overall cure rate with antibiotics alone was 67%, which was similar to that of peritonitis due to other organisms. Vancomycin was the most common antimicrobial agent administered in the initial empiric and subsequent antibiotic regimens, although outcomes were similar regardless of antimicrobial schedule. Corynebacterium peritonitis not infrequently resulted in relapse (18%), repeat peritonitis (15%), hospitalization (70%), catheter removal (21%), permanent haemodialysis transfer (15%) and death (2%). The individuals who had their catheters removed more than 1 week after the onset of Corynebacterium peritonitis had a significantly higher risk of permanent haemodialysis transfer than those who had their catheters removed within 1 week (90% versus 43%, P < 0.05).
CONCLUSIONS: Corynebacterium is an uncommon but significant cause of PD-associated peritonitis. Complete cure with antibiotics alone is possible in the majority of patients, and rates of adverse outcomes are comparable to those seen with peritonitis due to other organisms. Use of vancomycin rather than cephazolin as empiric therapy does not impact outcomes, and a 2-week course of antibiotic therapy appears sufficient. If catheter removal is required, outcomes are improved by removing the catheter within 1 week of peritonitis onset.

Entities:  

Mesh:

Year:  2009        PMID: 19574339     DOI: 10.1093/ndt/gfp322

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  14 in total

1.  Weekend compared with weekday presentations of peritoneal dialysis-associated peritonitis.

Authors:  David W Johnson; Philip Clayton; Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Stephen McDonald; Neil Boudville; Kathryn J Wiggins; Kym Bannister; Fiona Brown
Journal:  Perit Dial Int       Date:  2012-02-01       Impact factor: 1.756

2.  Is female sex really a risk factor for infectious death in peritoneal dialysis?

Authors:  David W Johnson; Yeoungjee Cho; Rajnish Mehrotra
Journal:  Perit Dial Int       Date:  2013 Sep-Oct       Impact factor: 1.756

Review 3.  Peritoneal dialysis-related infections recommendations: 2010 update. What is new?

Authors:  Olga Nikitidou; Vassilios Liakopoulos; Triantafillia Kiparissi; Maria Divani; Konstantinos Leivaditis; Nicholas Dombros
Journal:  Int Urol Nephrol       Date:  2011-07-09       Impact factor: 2.370

Review 4.  The Current State of Peritoneal Dialysis.

Authors:  Rajnish Mehrotra; Olivier Devuyst; Simon J Davies; David W Johnson
Journal:  J Am Soc Nephrol       Date:  2016-06-23       Impact factor: 10.121

Review 5.  Continuous Quality Improvement Initiatives to Sustainably Reduce Peritoneal Dialysis-Related Infections in Australia and New Zealand.

Authors:  Melissa Nataatmadja; Yeoungjee Cho; David W Johnson
Journal:  Perit Dial Int       Date:  2016-09-10       Impact factor: 1.756

6.  The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss
Journal:  Perit Dial Int       Date:  2012 Sep-Oct       Impact factor: 1.756

7.  Acute peritonitis due to Corynebacterium ulcerans in a patient receiving continuous ambulatory peritoneal dialysis: a case report and literature review.

Authors:  Yukihiro Kimura; Yasuko Watanabe; Norihiro Suga; Natsuko Suzuki; Kunihiro Maeda; Keisuke Suzuki; Wataru Kitagawa; Naoto Miura; Hiroyuki Morita; Hirokazu Imai
Journal:  Clin Exp Nephrol       Date:  2010-09-14       Impact factor: 2.801

8.  Peritonitis due to uncommon gram-positive pathogens in children undergoing peritoneal dialysis.

Authors:  J Dotis; N Printza; F Papachristou
Journal:  Hippokratia       Date:  2012-07       Impact factor: 0.471

9.  Effects of climatic region on peritonitis risk, microbiology, treatment, and outcomes: a multicenter registry study.

Authors:  Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Fiona G Brown; Neil Boudville; Kathryn J Wiggins; Kym M Bannister; Philip Clayton; David W Johnson
Journal:  Perit Dial Int       Date:  2012-09-01       Impact factor: 1.756

10.  The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study.

Authors:  Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Fiona G Brown; Neil Boudville M; Kathryn J Wiggins; Kym M Bannister; Philip Clayton; David W Johnson
Journal:  BMC Nephrol       Date:  2012-06-15       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.